AstraZeneca Says Imfinzi-Tremelimumab Combination Improves Lung Cancer Survival
September 09 2021 - 11:43AM
Dow Jones News
By Jaime Llinares Taboada
AstraZeneca PLC said Thursday that the combination of its
Imfinzi immunotherapy with tremelimumab antibodies improved
survival in lung cancer patients.
The pharmaceutical company said Imfinzi and tremelimumab with
chemotherapy improved overall survival by 23% in 1st-line Stage IV
non-small cell lung cancer at a Phase 3 trial.
"Adding a short course of tremelimumab to Imfinzi for those
patients already receiving chemotherapy, reduced the risk of cancer
progressing or death by 28% compared to chemotherapy alone," said
Susan Galbraith, AstraZeneca's executive vice president at Oncology
R&D.
Write to Jaime Llinares Taboada at jaime.llinares@wsj.com;
@JaimeLlinaresT
(END) Dow Jones Newswires
September 09, 2021 11:28 ET (15:28 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024
